EP1855719A4 - Neutralisierende monoklonale antikörper gegen coronaviren in zusammenhang mit schwerem akutem atemwegssyndrom - Google Patents

Neutralisierende monoklonale antikörper gegen coronaviren in zusammenhang mit schwerem akutem atemwegssyndrom

Info

Publication number
EP1855719A4
EP1855719A4 EP06720569A EP06720569A EP1855719A4 EP 1855719 A4 EP1855719 A4 EP 1855719A4 EP 06720569 A EP06720569 A EP 06720569A EP 06720569 A EP06720569 A EP 06720569A EP 1855719 A4 EP1855719 A4 EP 1855719A4
Authority
EP
European Patent Office
Prior art keywords
sars
cov
acute respiratory
respiratory syndrome
severe acute
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06720569A
Other languages
English (en)
French (fr)
Other versions
EP1855719A2 (de
Inventor
Shibo Jiang
Yuxian He
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York Blood Center Inc
Original Assignee
New York Blood Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Blood Center Inc filed Critical New York Blood Center Inc
Priority to DK10151641.7T priority Critical patent/DK2193802T3/da
Priority to EP10151641A priority patent/EP2193802B1/de
Publication of EP1855719A2 publication Critical patent/EP1855719A2/de
Publication of EP1855719A4 publication Critical patent/EP1855719A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP06720569A 2005-02-08 2006-02-08 Neutralisierende monoklonale antikörper gegen coronaviren in zusammenhang mit schwerem akutem atemwegssyndrom Withdrawn EP1855719A4 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DK10151641.7T DK2193802T3 (da) 2005-02-08 2006-02-08 Neutraliserende monoklonale antistoffer mod med svært akut respirationssyndrom associeret coronavirus
EP10151641A EP2193802B1 (de) 2005-02-08 2006-02-08 Neutralisierung monoklonaler Antikörper gegen mit schwerem akutem Respirationssyndrom assoziiertem Coronavirus

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65104605P 2005-02-08 2005-02-08
US14192505A 2005-05-31 2005-05-31
PCT/US2006/004599 WO2006086561A2 (en) 2005-02-08 2006-02-08 Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus

Publications (2)

Publication Number Publication Date
EP1855719A2 EP1855719A2 (de) 2007-11-21
EP1855719A4 true EP1855719A4 (de) 2009-11-04

Family

ID=36793717

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06720569A Withdrawn EP1855719A4 (de) 2005-02-08 2006-02-08 Neutralisierende monoklonale antikörper gegen coronaviren in zusammenhang mit schwerem akutem atemwegssyndrom

Country Status (10)

Country Link
EP (1) EP1855719A4 (de)
JP (1) JP2008529504A (de)
AT (1) ATE556717T1 (de)
AU (1) AU2006213775C1 (de)
BR (1) BRPI0606148A2 (de)
CA (1) CA2595780A1 (de)
ES (1) ES2384497T3 (de)
MX (1) MX2007009512A (de)
NZ (1) NZ560328A (de)
WO (1) WO2006086561A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3155004B1 (de) 2014-06-12 2021-01-13 Universidade do Porto - Reitoria Neonataler impfstoff
CA3166967A1 (en) * 2020-02-06 2021-08-12 Bert Schepens Corona virus binders
BR112022016574A2 (pt) * 2020-02-19 2023-02-14 United Biomedical Inc Peptídeos e proteínas projetadas para a detecção, prevenção e tratamento da doença de coronavirus, 2019 (covid-19)
CN113292650B (zh) * 2020-02-24 2022-08-12 中国科学院微生物研究所 新型冠状病毒的人源单克隆抗体及其应用
CN113292649B (zh) * 2020-02-24 2022-08-12 中国科学院微生物研究所 新型冠状病毒的人源单克隆抗体及其应用
BR112022017986A2 (pt) * 2020-03-09 2022-12-13 Abcellera Biologics Inc Anticorpos anticoronavírus e métodos de uso
CN119438581A (zh) * 2020-03-13 2025-02-14 科美诊断技术股份有限公司 一种用于检测新型冠状病毒中和抗体的试剂盒
CN111560074B (zh) * 2020-03-20 2021-07-09 中山大学 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白单区域亚单位纳米疫苗
CN111983226A (zh) * 2020-03-25 2020-11-24 新加坡国立大学 SARSr-CoV抗体的检测
WO2021202893A1 (en) * 2020-04-03 2021-10-07 Nonigenex, Inc. Detecting adaptive immunity to coronavirus
JP7174961B2 (ja) * 2020-05-01 2022-11-18 花王株式会社 抗ＳＡＲＳ－ＣｏＶ－２抗体を用いた医薬品及び検査キット
CN112010966B (zh) * 2020-05-15 2021-03-19 潍坊医学院 一种针对新冠病毒棘突蛋白非rbd区的单克隆抗体及其应用
WO2021238910A1 (en) * 2020-05-25 2021-12-02 Guo Bingshi Anti-coronavirus spike protein antibodies and uses thereof
CN112017782A (zh) * 2020-06-01 2020-12-01 北京松果天目健康管理有限公司 SARS-CoV-2易感性的检测方法及新冠病毒重症风险预测方法
EP4171603A4 (de) * 2020-06-25 2024-06-26 Gliknik Inc. Ace2-fc-fusionsproteine und verfahren zur verwendung
CN113945714B (zh) * 2020-07-16 2023-01-31 南京蓬勃生物科技有限公司 新型冠状病毒中和抗体类药物中和能力的检测方法
EP4545971A3 (de) 2020-07-16 2025-08-06 Caregen Co., Ltd. Peptid mit neutralisierender wirkung gegen schweres akutes respiratorisches syndrom-coronavirus 2
CN112010984B (zh) * 2020-08-04 2021-10-12 广州千扬生物医药技术有限公司 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白多聚体纳米疫苗
US20230312689A1 (en) 2020-08-26 2023-10-05 National University Corporation Kumamoto University Human antibody or antigen-binding fragment thereof against coronavirus spike protein
CN114181301B (zh) * 2020-09-14 2023-04-28 复旦大学 针对SARS-CoV-2的无ADE效应的中和抗体
CN113156129B (zh) * 2021-01-13 2022-04-05 广东菲鹏生物有限公司 中和抗体高敏检测方法及产品
WO2022161346A1 (en) * 2021-01-27 2022-08-04 Bioduro (Jiangsu) Co., Ltd. Antibody against sars-cov-2
CN113150130B (zh) * 2021-01-31 2022-10-18 中南大学湘雅医院 新型冠状病毒单克隆抗体及其应用
CN116973566A (zh) * 2021-02-03 2023-10-31 广东菲鹏生物有限公司 一种鉴别结合突变型抗原的抗体的方法及试剂
EP4089112A1 (de) * 2021-05-14 2022-11-16 Ustav organicke chemie a biochemie AV CR, v.v.i. Antikörper mit bindung an rbd des spike-proteins von sars-cov-2 und verfahren zur quantifizierung von schützenden antikörpern gegen sars-cov-2
WO2023148641A1 (en) * 2022-02-02 2023-08-10 Translational Health Science And Technology Institute Monoclonal antibodies specific to receptor binding domain of sars-cov2 and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BABCOCK GREGORY J ET AL: "Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor", JOURNAL OF VIROLOGY, vol. 78, no. 9, May 2004 (2004-05-01), pages 4552 - 4560, XP002546670, ISSN: 0022-538X *
HE Y ET AL: "Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 325, no. 2, 10 December 2004 (2004-12-10), pages 445 - 452, XP004626814, ISSN: 0006-291X *
TRAGGIAI E ET AL: "An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 10, no. 8, 11 July 2004 (2004-07-11), pages 871 - 875, XP002385893, ISSN: 1078-8956 *
XIAO X ET AL: "The SARS-CoV S glycoprotein: expression and functional characterization", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 312, no. 4, 26 December 2003 (2003-12-26), pages 1159 - 1164, XP004476398, ISSN: 0006-291X *

Also Published As

Publication number Publication date
ATE556717T1 (de) 2012-05-15
JP2008529504A (ja) 2008-08-07
AU2006213775C1 (en) 2011-11-03
NZ560328A (en) 2010-05-28
MX2007009512A (es) 2008-02-21
WO2006086561A2 (en) 2006-08-17
CA2595780A1 (en) 2006-08-17
AU2006213775B2 (en) 2010-11-11
BRPI0606148A2 (pt) 2009-06-02
EP1855719A2 (de) 2007-11-21
AU2006213775A1 (en) 2006-08-17
ES2384497T3 (es) 2012-07-05
WO2006086561A3 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
EP1855719A4 (de) Neutralisierende monoklonale antikörper gegen coronaviren in zusammenhang mit schwerem akutem atemwegssyndrom
FR23C1024I1 (fr) Composition stable d'une protéine anabolique osseuse qui est un analogue de pthrp, et ses emplois
NO20043245L (no) Bindingsproteiner som biosensorer
UA109633C2 (uk) Антитіло людини проти тканинного фактора
EA200970469A1 (ru) Антитела-агонисты рецептора trkb и их применение
CY1108689T1 (el) Ολιγοπεπτιδια για την ελαττωση αυξημενης συγκεντρωσεως της ουριας στο αιμα
CR8698A (es) Anticuerpos monoclonales al factor de crecimiento de hepatocito
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
WO2004111081A3 (en) Antigenic peptides of sars coronavirus and uses thereof
EA200870538A1 (ru) Лиофилизированные композиции анти-egfr антител
BRPI0314038B8 (pt) anticorpo humano isolado, molécula de ácido nucleico isolada, vetor, uso de um anticorpo, e, composição farmacêutica
MA33256B1 (fr) Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
NO20043259L (no) Bindingsproteiner som biosensorer
EA201000424A1 (ru) Антитела к il-23
EA200801071A1 (ru) Способы и композиции для применения в целях лечения пациентов с положительным по аутоантителам заболеванием
WO2005012337A3 (en) Antigenic peptides of sars coronavirus and uses thereof
ATE376559T1 (de) Methoden der verhinderung und behandlung der alzheimer'schen krankheit
NO20092522L (no) Sammensetninger og fremgangsmater for a behandle kreft med cupredoxiner og CPG rikt DNA
MX340547B (es) Equipos de prueba de diagnostico.
WO2003016464A3 (en) Cancer specific oligosaccharide sequences and use thereof
ATE497774T1 (de) Screening kombinatorischer proteinbibliotheken mittels periplasmatischer expression
GB2455929A (en) A method for the identification of human immunodeficiency virus related antibodies in blood
MX2007000916A (es) Anticuerpo enriquecido para detectar infeccion micobacteriana, metodos de uso y prueba de diagnostico que emplea la misma.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070828

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

DAX Request for extension of the european patent (deleted)
R17D Deferred search report published (corrected)

Effective date: 20090423

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/215 20060101ALI20090619BHEP

Ipc: A61K 39/42 20060101ALI20090619BHEP

Ipc: A61K 39/395 20060101ALI20090619BHEP

Ipc: A61K 39/00 20060101AFI20090619BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20091002

17Q First examination report despatched

Effective date: 20100408

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100819